SS Innovations Appoints Sarah M. Romano as Chief Financial Officer
SS Innovations (Nasdaq: SSII) has appointed veteran medtech finance executive Sarah M. Romano as Chief Financial Officer, effective August 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SS Innovations (Nasdaq: SSII) has appointed veteran medtech finance executive Sarah M. Romano as Chief Financial Officer, effective August 3, 2026. She will be based in the United States and is expected to support the company’s next phase of global growth.
According to SS Innovations, Romano brings over 20 years of financial leadership in medical technology and life sciences, including CFO roles at Vicarious Surgical, Entero Therapeutics and Kiora Pharmaceuticals, where she led capital strategy, strategic transactions and SEC reporting, and helped raise more than $100 million through public and private financings.
Positive
- New CFO appointed effective August 3, 2026
- Over two decades of medtech and life sciences finance experience
- More than $100 million raised across public and private financings
Negative
- None.
Details
News Market Reaction – SSII
On Jul 14, the day this news came out, SSII closed 0.82% above the previous close. Argus tracked a peak move of +2.9% during that session. Our momentum scanner recorded 5 alerts for this stock that day. Relative volume reached 1.5x the daily average during tracking.
Data tracked by StockTitan Argus for the Jul 14 session.
Key Figures
- CFO start date
- August 3, 2026
- Effective date of Chief Financial Officer appointment
- Industry experience
- more than two decades
- Medtech and life sciences finance leadership
- Capital raised
- more than $100 million
- Public and private financings led by incoming CFO
Historical Context
-
Subsidiary SSICRS graduated first cardiac robotic surgery training class.
-
Named Outstanding Company winner at 2026 Surgical Robotics Industry Awards.
-
Reported completion of world’s longest-distance robotic telesurgery using SSi Mantra.
-
Record Q1 2026 revenue with higher gross margin and narrower net loss.
-
Demonstrated long-distance cross-border telesurgery at surgical congress.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sec reporting regulatory
certified public accountant (cpa) financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Veteran medtech finance executive brings extensive public company and capital markets experience to support the Company's next phase of global growth
FORT LAUDERDALE, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- via IBN -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Sarah M. Romano as Chief Financial Officer, effective August 3, 2026. Ms. Romano will be based in the United States.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We are thrilled to welcome Sarah as our Chief Financial Officer at this critical moment in our growth journey. As we continue our global expansion, including pursuing U.S. FDA approval of our advanced, cost-effective SSi Mantra surgical robotic system, Sarah brings strong financial leadership, keen strategic vision, and extensive capital markets experience. She will play an integral role in scaling and enhancing our financial operations to accommodate our anticipated growth.”
Ms. Romano added, “I am delighted for this opportunity to collaborate closely with Dr. Sudhir and the leadership team as SS Innovations delivers on its mission to democratize global access to cutting-edge surgical robotic care.”
Ms. Romano is a seasoned public company finance executive, bringing more than two decades of experience leading capital strategy, corporate growth, and financial operations in the medical technology and life sciences industries. Most recently, Ms. Romano served as Chief Financial Officer of Vicarious Surgical, a robotic surgery company where she led financial and operational initiatives to significantly reduce cash burn, strengthen the balance sheet, and support the company's strategic objectives. Previously, she served as Chief Financial Officer of Entero Therapeutics and Kiora Pharmaceuticals, where she led capital raising activities, strategic transactions, SEC reporting, and investor relations programs. Throughout her career, Ms. Romano has raised more than
Ms. Romano began her career as an auditor at PricewaterhouseCoopers and is a licensed Certified Public Accountant (CPA) in Massachusetts. She earned a Bachelor of Arts in Accounting from the College of the Holy Cross and Master of Accountancy in Accounting from Boston College.
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
About the SSi Mantra
The SSi Mantra is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient-related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com
Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com
Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.ai
512.354.7000 Office
Editor@IBN.Ai
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.